X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
‘1473 (23ME-01473) is a dual mechanism antibody which works targeting ULBP6 to restore anti-tumor immunity through NK and T cells. It is being evaluated for the treatment of advanced solid tumors.
Lead Product(s): 23ME-01473
Therapeutic Area: Oncology Product Name: ‘1473
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
‘1473 (23ME-01473) is an antibody that targets ULBP6, which can be expressed and secreted by tumor cells to suppress immune activity. It is being evaluated in preclinical studies for the treatment of advanced solid tumors.
Lead Product(s): 23ME-01473
Therapeutic Area: Oncology Product Name: ‘1473
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
23ME-00610 is a high-affinity, fully humanized monoclonal antibody that is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. It is under phase 1/2 clinical development for the treatment of advanced neuroendocrine and ovarian cancer.
Lead Product(s): 23ME-00610
Therapeutic Area: Oncology Product Name: 23ME-00610
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
23ME-00610 is a high-affinity, fully humanized monoclonal antibody that is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. The CD200–CD200R1 axis is an immunological checkpoint that plays a pivotal role in maintenance of immune tolerance.
Lead Product(s): 23ME-00610
Therapeutic Area: Oncology Product Name: 23ME-00610
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2023
Details:
23ME-00610 is a, fully humanized mAb that is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. CD200R1 is an inhibitory receptor expressed on T cells and myeloid cells while CD200, ligand of CD200R1, is highly expressed on certain tumors.
Lead Product(s): 23ME-00610
Therapeutic Area: Oncology Product Name: 23ME-00610
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
23ME-00610 is a high-affinity humanized monoclonal antibody that is designed to bind to the CD200R1 receptor and prevent the interaction of CD200 and CD200R1. The CD200–CD200R1 axis is an immunological checkpoint that plays a pivotal role in maintenance of immune tolerance.
Lead Product(s): 23ME-00610
Therapeutic Area: Oncology Product Name: 23ME-00610
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
SLCO1B1 (simvastatin) is a medication in the statin family of drugs, commonly prescribed to lower cholesterol to help reduce the risk of heart attack and stroke.
Lead Product(s): Simvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLCO1B1
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
23ME-00610 is a high-affinity humanized monoclonal antibody that is designed to bind to the CD200R1 receptor and prevent the interaction of CD200 and CD200R1. The CD200–CD200R1 axis is an immunological checkpoint that plays a pivotal role in maintenance of immune tolerance.
Lead Product(s): 23ME-00610
Therapeutic Area: Oncology Product Name: 23ME-00610
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
23ME-00610 is a first-in-class wholly-owned immuno-oncology (I/O) antibody to enter the clinic targets the CD200R1 immune checkpoint to enhance T cell-mediated antitumor activity.
Lead Product(s): 23ME-00610
Therapeutic Area: Oncology Product Name: 23ME-00610
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
Phase 1 clinical trial is initiated for 23ME-00610 on the basis of results from preclinical data which indicate that mechanism has the potential to reinvigorate tumor-exhausted T-cells and myeloid cells to restore their ability to kill cancer cells.
Lead Product(s): 23ME-00610
Therapeutic Area: Oncology Product Name: 23ME-00610
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
